Last updated: September 23, 2026
HYFTOR, Nobelpharma’s topical sirolimus gel, is an FDA-approved treatment for facial angiofibroma associated with tuberous sclerosis complex, or TSC. Its commercial profile is defined by a small but identifiable patient population, orphan-drug protection, chronic use potential, and competition from compounded topical sirolimus and existing TSC therapies. Nobelpharma is privately held and does not disclose standalone HYFTOR revenue, making public financial modeling dependent on patient-volume, pricing, access, and persistence assumptions rather than reported product sales.
What is HYFTOR and what disease does it treat?
HYFTOR is a 0.2% sirolimus topical gel approved in the United States for the topical treatment of facial angiofibroma associated with TSC in adults and pediatric patients age 6 years and older.[1]
TSC is a genetic disorder involving mutations in the TSC1 or TSC2 genes. Facial angiofibromas are benign vascular and fibrous lesions that commonly develop during childhood or adolescence. They can bleed, cause discomfort, and create visible facial changes.
| Attribute |
HYFTOR |
| Active ingredient |
Sirolimus |
| Dosage form |
Topical gel |
| Strength |
0.2% |
| FDA indication |
Facial angiofibroma associated with TSC |
| Minimum approved age |
6 years |
| U.S. sponsor |
Nobelpharma America LLC |
| FDA approval date |
May 26, 2022 |
| Regulatory designation |
Orphan-drug product |
| Primary commercial market |
United States specialty and rare-disease market |
The product applies locally to facial lesions and is positioned differently from oral mTOR inhibitors such as everolimus, which are used for certain TSC-associated tumors and seizures but carry systemic exposure and monitoring requirements.[2]
When did HYFTOR receive FDA approval and lose exclusivity?
HYFTOR received FDA approval on May 26, 2022. The product qualified for orphan-drug exclusivity, which generally provides seven years of market exclusivity for the approved indication under the Orphan Drug Act.[3]
On that basis, the core FDA orphan exclusivity period is expected to run through May 2029, subject to the scope of the designation and applicable regulatory events. Orphan exclusivity does not prevent all competing products from entering the market. It generally blocks FDA approval of the same drug for the same orphan indication unless the competing product is clinically superior or otherwise falls outside the exclusivity scope.
The product may also benefit from patent protection, pediatric incentives, formulation rights, and regulatory barriers separate from orphan exclusivity. Those protections should not be treated as interchangeable. Orphan exclusivity is indication-specific; patents may cover the formulation, manufacturing process, use, or delivery system.
HYFTOR exclusivity timeline
| Date |
Event |
| May 26, 2022 |
FDA approval for facial angiofibroma associated with TSC |
| 2022 |
U.S. commercial launch |
| 2022-2029 |
Expected core orphan-drug exclusivity period |
| 2029 onward |
Higher risk of competing FDA approvals, subject to patents and regulatory scope |
| Post-2029 |
Compounded topical sirolimus remains a commercial and clinical alternative regardless of FDA exclusivity |
No public source establishes a single “generic entry date” for HYFTOR. A post-2029 entrant would still face potential patent litigation, formulation differences, and the need to demonstrate regulatory suitability.
How large is the HYFTOR market?
HYFTOR addresses a narrow rare-disease market rather than the broader dermatology market. Published TSC prevalence estimates vary, but the condition is generally considered to affect approximately one in 6,000 to one in 10,000 live births.[4] The number of patients with facial angiofibroma is smaller than the total TSC population because lesion severity and treatment need vary.
The commercial opportunity has four constraints:
- The indication is limited to TSC-associated facial angiofibroma.
- Many patients may receive no drug treatment or may use procedural therapy.
- Compounded topical sirolimus has historically been available through specialty pharmacies.
- Treatment is applied to visible lesions and may require long-term or repeated use, creating refill potential but also adherence risk.
The market has attractive orphan-drug economics if reimbursement is secured. A small patient population can support substantial annual revenue when treatment is chronic and the product is priced as a branded specialty therapy. The same pricing strategy can create prior-authorization, step-therapy, and patient-assistance burdens.
What is known about HYFTOR revenue and financial trajectory?
Nobelpharma is privately held, and it does not publish a public company filing that isolates HYFTOR sales, gross profit, prescriptions, or patient counts. No audited standalone HYFTOR revenue figure can be established from FDA materials.
The most defensible financial assessment is therefore directional:
| Period |
Financial trajectory |
Main drivers |
| 2022-2023 |
Launch and market-education phase |
Payer coverage, diagnosis, physician adoption, specialty-pharmacy distribution |
| 2024-2026 |
Expansion phase |
Reimbursement improvement, patient persistence, increased recognition of topical mTOR treatment |
| 2027-2029 |
Maturity before exclusivity pressure |
Retention of treated patients, price discipline, lifecycle management |
| 2030 onward |
Risk-adjusted phase |
Patent position, competing approvals, compounded alternatives, pricing pressure |
HYFTOR’s revenue model is likely more sensitive to treated-patient count and net price than to broad market share. A simple commercial framework is:
Annual product revenue = treated patients × annual net treatment cost × persistence
The main variables are not publicly disclosed. Gross sales may materially overstate net revenue because specialty pharmaceuticals commonly face rebates, co-pay assistance, distribution discounts, and payer concessions.
What could increase HYFTOR revenue?
Revenue expansion could come from:
- Earlier diagnosis of TSC and facial angiofibroma.
- Increased use in pediatric patients.
- Conversion from compounded sirolimus to FDA-approved product.
- Greater payer acceptance after real-world treatment experience.
- Long-term maintenance treatment.
- Wider adoption by dermatologists, pediatricians, neurologists, and TSC specialty centers.
The strongest commercial argument is product standardization. HYFTOR provides a defined concentration, manufacturing process, labeling framework, and FDA-reviewed quality profile. Those attributes can support conversion from compounded preparations, although price differences may limit conversion.
What could constrain revenue?
The principal constraints are:
- Small addressable population.
- High out-of-pocket exposure if coverage is restricted.
- Competition from compounded topical sirolimus.
- Use of laser or surgical procedures for selected lesions.
- Variable severity and treatment persistence.
- Limited physician familiarity outside specialist centers.
What competitive products challenge HYFTOR?
HYFTOR competes with treatments rather than with a single branded product.
Compounded topical sirolimus
Compounded sirolimus creams, ointments, and gels are the most direct alternative. They may offer lower cost and flexible concentrations, but they do not necessarily have the same FDA-approved indication, standardized commercial presentation, or label-based dosing framework.
Compounding creates a persistent price threat because it can remain available even after HYFTOR’s orphan exclusivity expires. FDA approval of HYFTOR does not eliminate lawful compounding in every circumstance.
Laser and procedural treatment
Pulsed-dye laser, ablative laser, and other dermatologic procedures may be used for selected patients. Procedures can reduce visible lesions quickly but may require repeat treatment and can carry risks of pain, scarring, pigmentary change, or recurrence.
Oral mTOR inhibitors
Everolimus and other systemic mTOR inhibitors are relevant to the broader TSC treatment landscape. They are not direct substitutes for routine localized facial angiofibroma treatment in every patient because systemic exposure and monitoring requirements are materially different.[2]
What FDA and Orange Book status applies to HYFTOR?
HYFTOR is an FDA-approved prescription product regulated under a new drug application. The FDA approval established the indication, formulation, strength, age range, labeling, and safety information.[1]
The Orange Book is the primary FDA source for therapeutic-equivalence evaluations and listed patent or exclusivity information. A commercial assessment should distinguish:
- FDA approval status.
- Listed patents, if any.
- Orphan-drug exclusivity.
- Pediatric exclusivity.
- Patent-term adjustment or extension.
- Regulatory exclusivity for specific indications.
Orphan-drug exclusivity is the clearest publicly established protection for HYFTOR through the initial seven-year period. The commercial impact of Orange Book-listed patents depends on the specific claims, expiration dates, listing status, and whether a challenger files a Paragraph IV certification.
Which companies are challenging HYFTOR with Paragraph IV filings?
No widely reported Paragraph IV litigation or approved generic challenge has established a public launch path for HYFTOR. The absence of a reported challenge does not prove that no certification has been filed, because early regulatory activity may not produce immediate public litigation or commercial impact.
A Paragraph IV challenge would typically target an Orange Book-listed patent and allege invalidity, unenforceability, or non-infringement. For a topical product, likely technical dispute areas could include:
- Gel composition.
- Sirolimus concentration.
- Particle size or solubility.
- Skin penetration and delivery characteristics.
- Manufacturing controls.
- Methods of treating facial angiofibroma.
A competing product could also pursue a different formulation or a different regulatory route, reducing dependence on the exact patent claims protecting HYFTOR.
What patents protect HYFTOR?
HYFTOR’s practical IP protection is likely to depend on formulation and topical-delivery patents rather than on the basic sirolimus molecule, which is an older active ingredient.
Relevant protection categories include:
| IP category |
Commercial purpose |
| Formulation patents |
Protect gel composition, excipients, concentration, and physical properties |
| Method-of-use patents |
Protect treatment of facial angiofibroma or related TSC manifestations |
| Manufacturing patents |
Protect preparation, dispersion, uniformity, and stability methods |
| Device or packaging rights |
Protect dosing, application, or product presentation |
| Trade secrets |
Protect process parameters and quality-control methods |
The strength of the patent estate depends on claim breadth and validity, not on the number of filings. Narrow formulation claims may be designed to protect the marketed product while leaving alternative topical formulations open. Manufacturing trade secrets may create practical barriers but are harder to enforce against independent development.
What litigation and settlement risks affect HYFTOR?
No major publicly reported HYFTOR patent settlement has defined the generic-entry timetable. The most relevant litigation risk would arise if a competitor develops an FDA-suitable topical sirolimus formulation and seeks approval before or after the orphan-exclusivity period.
Potential settlement outcomes could include:
- Delayed generic or alternative-product entry.
- A licensed launch date.
- Restrictions on the challenged indication.
- A formulation redesign by the challenger.
- No settlement, followed by patent litigation through trial or appeal.
For a rare-disease product, litigation economics may be less attractive to challengers because the market is small. That factor can delay challenges, but it does not eliminate them if the branded product commands a high net price.
How strong is the HYFTOR patent and commercial estate?
HYFTOR has a stronger regulatory position than its molecule-level IP position. Sirolimus is an established drug, so exclusivity must rely on the approved topical formulation, indication, manufacturing process, and orphan designation.
Strengths
- FDA approval for a defined rare-disease indication.
- Seven-year orphan exclusivity framework.
- First branded FDA-approved topical sirolimus product for this indication in the U.S.
- Potential for chronic use.
- Specialist-center adoption and disease-awareness advantages.
- Product standardization versus compounded alternatives.
Weaknesses
- Narrow patient population.
- Older active ingredient with limited molecule-level exclusivity.
- Compounded topical competition.
- Potentially narrow formulation claims.
- Reimbursement sensitivity.
- No public standalone revenue disclosure to demonstrate commercial scale.
The estate is commercially defensible but not insulated. Its value depends on converting patients from compounding and procedures while maintaining payer access before the end of orphan protection.
How does HYFTOR compare with compounded sirolimus?
| Factor |
HYFTOR |
Compounded topical sirolimus |
| FDA-approved indication |
Yes |
Generally no equivalent branded approval |
| Dose and formulation standardization |
Defined commercial product |
May vary by pharmacy |
| Regulatory evidence |
FDA-reviewed |
Depends on compounding framework |
| Price |
Likely higher |
Often lower |
| Payer positioning |
Specialty-drug authorization |
May face separate coverage rules |
| Manufacturing consistency |
Commercial GMP framework |
Pharmacy-dependent |
| Competitive threat |
Direct |
Persistent throughout product life |
The central market-access question is whether payers and prescribers value FDA approval enough to justify the price premium over compounding.
What generic entry scenarios exist for HYFTOR?
Three scenarios are most relevant:
- Delayed entry: Orphan exclusivity, patents, and limited market size deter challengers until after 2029.
- Formulation-specific entry: A competitor develops a different topical sirolimus formulation that avoids key claims and seeks approval through an appropriate pathway.
- Compounding-led erosion: HYFTOR loses share without a conventional generic because lower-cost compounded products remain available.
The third scenario is commercially important. A branded rare-disease product can face price pressure before formal generic approval if physicians and payers accept compounded alternatives.
Key Takeaways
- HYFTOR is a 0.2% topical sirolimus gel approved by the FDA in May 2022 for facial angiofibroma associated with TSC.
- Its expected seven-year orphan-drug exclusivity period runs through approximately May 2029.
- Nobelpharma does not publicly disclose standalone HYFTOR revenue or patient counts.
- Revenue potential depends on chronic treatment, specialty reimbursement, and conversion from compounded topical sirolimus.
- The principal competitive threats are compounding, laser procedures, and alternative TSC therapies rather than an established branded substitute.
- The product’s commercial IP is likely concentrated in formulation, use, manufacturing, and delivery rights because sirolimus itself is an old molecule.
- No major publicly reported Paragraph IV challenge or settlement currently defines generic entry.
- HYFTOR has a defensible rare-disease position, but its long-term value is constrained by the small market and persistent compounded-product competition.
FAQs
Is HYFTOR a biologic or a generic drug?
HYFTOR is a small-molecule sirolimus drug delivered as a topical gel. It is not a biologic and is not a generic product.
Can patients use compounded sirolimus instead of HYFTOR?
Compounded topical sirolimus may be used as an alternative under applicable prescribing and compounding rules. Its concentration, vehicle, stability, and quality controls may differ from HYFTOR.
Does HYFTOR treat all manifestations of tuberous sclerosis complex?
No. HYFTOR is approved for facial angiofibroma associated with TSC. It is not approved to treat every TSC manifestation, such as seizures, renal angiomyolipomas, or subependymal giant cell astrocytomas.
What is the biggest financial risk to HYFTOR?
The largest risk is limited patient volume combined with payer resistance to the branded price premium over compounded topical sirolimus.
What is the most likely post-2029 competitive threat?
The most likely threat is commercial erosion from compounded or alternative topical sirolimus products, followed by a potential FDA-approved competing formulation if the market supports development costs.
References
-
U.S. Food and Drug Administration. (2022). HYFTOR (sirolimus) topical gel prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215064s000lbl.pdf
-
U.S. Food and Drug Administration. (2022). AFINITOR and AFINITOR DISPERZ prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/022334s031,022344s031,203985s017lbl.pdf
-
U.S. Food and Drug Administration. (2024). Orphan drug designation and exclusivity. https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products
-
National Organization for Rare Disorders. (2023). Tuberous sclerosis complex. https://rarediseases.org/rare-diseases/tuberous-sclerosis-complex/
